

Pancreatic Cancer Committee meeting 8

Date: 08/02/2017

Location: RCOG, London

Minutes: Confirmed

Committee members present:	
John Primrose (Chair)	(Present for notes 1 – 4)
John Neoptolemos (Clinical Lead)	(Present for notes 1 – 4)
Fiona Campbell	(Present for notes 1 – 4)
Richard Charnley	(Present for notes 1 – 4)
Pippa Corrie	(Present for notes 1 – 4)
Lesley Goodburn	(Present for notes 1 – 4)
Philip Whelan	(Present for notes 1 – 4)
Derek O'Reilly	(Present for notes 1 – 4)
Kofi Oppong	(Present for notes 1 – 4)
Anna Jewell	(Present for notes 3 – 4)
Dawn Elliot	(Present for notes 1 – 4)
Mark Callaway	(Present for notes 1 – 4)
Laura McGeeney (via teleconference)	(Present for notes 3 - 4)

In attendance:		
Katie Perryman Ford	NICE Guideline Commissioning Manager	(Present for notes 1 – 3)
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 4)
James Hawkins	NGA Health Economist	(Present for notes 1 – 4)
Ferruccio Pelone	NGA Assistant Reviewer	(Present for notes 1 – 4)
Linyun Fou	NGA Systematic Reviewer	(Present for notes 1 – 4)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1 – 4)

Observers:	
None	

Apologies:	
Mark Callaway	Committee member



Suzanne Joharchi	Committee member
Somnath Mukherjee	Committee member
Margred Capel	Committee member
Katie Perryman Ford	NICE Guideline Commissioning Manager
John Graham	NGA Clinical Advisor
Fionnuala O'Brien	NGA Project Manager
Kelly Williams	NHA Assistant Systematic Reviewer

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 8th meeting on Pancreatic Cancer.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: reviewing the clinical and economic evidence for topic 5D and reviewing the clinical evidence for topic 5C.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pancreatic cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

No new interests were declared.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations

The Chair introduced James Hawkins, Health Economist, who gave a presentation about the NMA analysis and economic evidence for question 5D of the guideline. James then took questions from the group.



The Chair introduced Ferruccio Pelone, Assistant Systematic Reviewer, who gave a presentation on the clinical evidence for question 5D. Ferruccio then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

The Chair introduced Linyun Fou, Systematic Reviewer, who gave a presentation on the clinical evidence for question 5C. Lin then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

5. Questions and discussion

The Committee discussed the clinical and economic evidence presented for questions 5D and 5C. They drafted recommendations and the section of the guideline linking evidence to recommendations.

6. Any other business

No service user or carer concerns were raised.

Date of next meeting: 20/03/2017 & 21/03/2017

Location of next meeting: 20/03/2017 – RCOG, London

21/03/2017 – EEF Broadway House, London